Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
CytoDyn (CYDY)
OTHER OTC:CYDY
CytoDyn (CYDY) Stock Price & Analysis
591 Followers
CYDY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.15 - $1.26
Previous Close$0.26
Volume2.79M
Average Volume (3M)2.16M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$2.40M
Total Debt (Recent Filing)$37.28M
Price to Earnings (P/E)-1.0
Beta0.35
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price TargetN/A
EPS (TTM)-0.27
Shares Outstanding832,970,710
R-Squared0.00047
Standard Deviation0.49
10 Day Avg. Volume1,774,553
30 Day Avg. Volume2,157,018
Price to Book (P/B)-1.89
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-6.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target UpsideN/A
Rating ConsensusN/A
Alpha0.06
Number of Analyst Covering0
CytoDyn News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CYDY FAQ
What was CytoDyn’s price range in the past 12 months?
CytoDyn lowest stock price was $0.15 and its highest was $1.26 in the past 12 months.
What is CytoDyn’s market cap?
Currently, no data Available
When is CytoDyn’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CytoDyn’s earnings last quarter?
Currently, no data Available
Is CytoDyn overvalued?
According to Wall Street analysts CytoDyn’s price is currently Overvalued.
Does CytoDyn pay dividends?
CytoDyn does not currently pay dividends.
What is CytoDyn’s EPS estimate?
CytoDyn’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CytoDyn have?
CytoDyn has 832,970,700 shares outstanding.
What happened to CytoDyn’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CytoDyn?
Currently, no hedge funds are holding shares in CYDY
---
CytoDyn Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.43%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-93.18%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
CytoDyn
CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. Its product include HIV, cancer, graft-versus-host disease (GVHD), and PCa test. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.
---
Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.
Heron Therapeutics
―
Prelude Therapeutics
―
Oyster Point Pharma
―
Generation Bio
―
Viking Therapeutics
―
---